Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements - Additional Information (Details)

v3.24.1
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Investment, Type [Extensible Enumeration]   Equity Securities [Member] Equity Securities [Member]  
Estimated fair value of equity securities   $ 41,937 $ 32,020  
Unrealized gain (loss) on equity securities   $ 9,917 12,130 $ (4,454)
Realized gain (loss) on equity securities     $ 4,074  
Vaxcyte, Inc. | Vaxcyte Common Stock        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Number of shares held   667,780 667,780  
Estimated fair value of equity securities   $ 41,900 $ 32,000  
Unrealized gain (loss) on equity securities   $ 9,900 $ 12,100 $ (4,500)
Shares of common stock   0 1,058,434  
Realized gain (loss) on equity securities     $ 4,100  
Blackstone Life Sciences | Royalty | 2015 License Agreement        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Revenue interest percentage 4.00% 4.00%    
Fair Value Measurements Recurring        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Securities held   $ 371,498 $ 330,430